Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management
Zubair A, Roy B, Baehring J, Nowak R. Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. Cureus 2022, 14: e30638. PMID: 36439604, PMCID: PMC9683636, DOI: 10.7759/cureus.30638.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitor therapyMyasthenia gravisCheckpoint inhibitorsInhibitor therapyICI therapyImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useInflammatory adverse effectsBest treatment algorithmCell lung cancerCheckpoint inhibitor useRenal cell cancerSystem side effectsPotential treatment optionNeurologic complicationsInhibitor useAcute managementOncologic treatmentAnti-CTLA4Cell cancerClinical outcomesTreatment algorithmClinical manifestationsTreatment options